Candriam S.C.A. Buys 22,425 Shares of Kenvue Inc. $KVUE

Key Points

• Candriam S.C.A. has increased its stake in Kenvue Inc. by 19.9%, now holding 135,052 shares valued at approximately $3.24 million.
• Kenvue's quarterly earnings report showed an EPS of $0.29, exceeding expectations, but revenue fell by 4% year-over-year to $3.84 billion.
• The company has announced a quarterly dividend increase to $0.2075 per share, representing an annualized yield of 3.8%.

Candriam S.C.A. raised its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 19.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 135,052 shares of the company's stock after acquiring an additional 22,425 shares during the quarter. Candriam S.C.A.'s holdings in Kenvue were worth $3,239,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in KVUE. Pittenger & Anderson Inc. bought a new position in shares of Kenvue during the first quarter worth approximately $30,000. TruNorth Capital Management LLC bought a new position in shares of Kenvue during the first quarter worth approximately $36,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after purchasing an additional 1,287 shares during the period. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Kenvue by 120.6% during the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock worth $41,000 after purchasing an additional 929 shares during the period. Finally, Clarity Asset Management Inc. bought a new position in shares of Kenvue during the fourth quarter worth approximately $45,000. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

KVUE has been the topic of several analyst reports. Bank of America reduced their price target on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, July 15th. JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Canaccord Genuity Group reduced their price target on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Citigroup cut their target price on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Finally, Royal Bank Of Canada cut their target price on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a research report on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $24.38.

Kenvue Trading Down 1.9%

NYSE KVUE traded down $0.42 during mid-day trading on Monday, reaching $21.19. 8,122,262 shares of the stock were exchanged, compared to its average volume of 18,577,858. Kenvue Inc. has a one year low of $19.75 and a one year high of $25.17. The stock has a 50 day simple moving average of $21.51 and a 200-day simple moving average of $22.46. The stock has a market cap of $40.67 billion, a P/E ratio of 28.64, a P/E/G ratio of 3.10 and a beta of 0.83. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter last year, the firm earned $0.32 earnings per share. Kenvue's quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th will be paid a dividend of $0.2075 per share. This is a boost from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend is Wednesday, August 13th. Kenvue's payout ratio is 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.